Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 575 of 5804
-
New drug combo aims to shrink lung tumors before surgery
Disease control Recruiting nowThis is a randomized, controlled, double-blind, multicenter Phase 3 clinical study to assess the efficacy and safety of envafolimab plus platinum-based doublet chemotherapy versus placebo plus platinum-based doublet chemotherapy as neoadjuvant/adjuvant therapy in subjects with re…
Phase: PHASE3 • Sponsor: 3D Medicines (Sichuan) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could a Drug-Radiation combo tame brain tumors?
Disease control TerminatedTo determine the safety and efficacy of using the drug azeliragon combined with stereotactic radiosurgery. Specifically, to determine if this combination will lead to improved response in the brain (tumor shrinking in size) and overall tumor control (how long tumor remains contro…
Phase: PHASE1, PHASE2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New device aims to improve survival and reduce hospital stays for lung clot patients
Disease control OngoingThis study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.
Phase: NA • Sponsor: Inari Medical • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Could a Chemo-Immunotherapy combo beat standard care for tough lung cancer?
Disease control OngoingThe current study is intended to be a "proof of concept" to evaluate the potential value of synergy between paclitaxel carboplatin and immunotherapy. If a signal clearly shows superiority over the CASPIAN data , we will have arguments to think that the combination of paclitaxel a…
Phase: PHASE2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New combo shows promise against Hard-to-Treat breast cancer
Disease control CompletedThe purpose of this study is to evaluate the safety and efficacy of samuraciclib in combination with fulvestrant versus fulvestrant alone in adult participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-neg…
Phase: PHASE2 • Sponsor: Carrick Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Can a clot-busting procedure help stroke patients with prior disabilities?
Disease control Recruiting nowTESTED will compare the risks and benefits of endovascular thrombectomy (EVT) to medical management (no EVT) in ischemic stroke patients who have a blockage in one of the large blood vessels in the brain and have a moderate-to-severe disability prior to their stroke.
Sponsor: University of Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for Hard-to-Treat GI cancers? phase II trial launches
Disease control Recruiting nowThis phase II study is a clinical study to explore the efficacy and safety of SI-B003 Monotherapy, BL-B01D1+SI-B003 Combination Therapy and BL-B01D1+PD-1 Monoclonal Antibody in patients with locally advanced or metastatic esophageal cancer, gastric cancer, colorectal cancer and o…
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Supercharged immune cells take on tough lymphoma
Disease control Recruiting nowA Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma
Phase: EARLY_PHASE1 • Sponsor: He Huang • Aim: Disease control
Last updated Jun 26, 2026 19:06 UTC
-
New program aims to prevent lymphedema in breast cancer patients
Prevention Recruiting nowThe purpose of this study to test whether a comprehensive program may help the lymph fluid to drain out of the arm and prevent lymphedema in participants with breast cancer.
Phase: PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 07:56 UTC
-
New hope for advanced breast cancer: OP-1250 faces off against standard care
Disease control Recruiting nowThis phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inh…
Phase: PHASE3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo therapy aims to boost immune attack on liver tumors
Disease control Recruiting nowAtezolizumab (anti-programmed death-ligand 1; anti-PD-L1) in conjunction with bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) has become the established standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC). Despite an improved ob…
Phase: PHASE2 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Brain pacemaker aims to quiet seizures and boost memory
Disease control Recruiting nowIn this study, participants will receive unilateral Deep Brain Stimulation (DBS) for treatment of epilepsy, with network-based stimulation targets specifically defined using a stereo-electro-encephalographic evaluation and chronic recordings using the Medtronic Percept™ primary c…
Phase: NA • Sponsor: Nitin Tandon • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for Late-Stroke patients: clot removal may work even days later
Disease control CompletedThe aim of this study is to assess the efficacy and safety of endovascular treatment versus medical management in patients with acute basilar artery occlusion with extended time window of 24-72 hours from onset.
Phase: NA • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New RA pill takes on tofacitinib in Head-to-Head trial
Disease control OngoingA randomized, double-blind, double-dummy, positive-controlled, phase 3 study to assess the safety and efficacy of TLL-018 in active rheumatoid arthritis subjects who had an inadequate response or intolerance to Biologic DMARDs.
Phase: PHASE3 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New COVID booster shows promise in trial
⭐️ VACCINE ⭐️ CompletedThis is a phase IIb/III, double-blind, randomised, active-controlled, multi-centre, non-inferiority clinical trial that aims to determine safety, tolerability and immunogenicity of a booster vaccination with a recombinant protein receptor binding domain (RBD) fusion homodimer of …
Phase: PHASE2, PHASE3 • Sponsor: Hipra Scientific, S.L.U • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 11:01 UTC
-
Breakthrough device could save babies stuck in birth canal
Disease control Recruiting nowProspective, multi-center, single arm with historical control, to verify the safety and effectiveness of the Yaari Extractor used by board certified or board eligible U.S. OB/GYN physicians in the management of shoulder dystocia.
Phase: NA • Sponsor: FetalEase Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control OngoingThis is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with moderate to severe atopic dermatitis. The estimated duration is…
Phase: PHASE2 • Sponsor: Nektar Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Spinal zap plus robot suit boosts walking recovery in new trial
Symptom relief OngoingThe goal of this clinical trial is to investigate the effects of transcutaneous spinal cord stimulation (TSCS) combined with exoskeleton training, as compared to exoskeleton training alone to improve motor function in individuals with incomplete spinal cord injury who are 12 mont…
Phase: NA • Sponsor: Craig Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
Promising drug may reduce eye bulging in thyroid disease
Disease control OngoingThe purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Brain wave tool may predict awakening in coma patients
Knowledge-focused Recruiting nowEvaluating the prognosis of comatose patients after cardiac arrest (CA) in the intensive care unit (ICU) remains challenging. It requires a multimodal approach combining standardized clinical examination, serum biomarkers, imaging and classically electrophysiological examinations…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC